Ocular Imaging With Spectral Domain Optical Coherence Tomography
NCT ID: NCT00926549
Last Updated: 2009-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
300 participants
INTERVENTIONAL
2009-05-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retinal Thickness Analysis Using Optical Coherence Tomography
NCT00797134
Agreement Between Spectral Domain and Time Domain Optical Coherence Tomography (OCT)
NCT00651989
Spectral-domain Optical Coherence Tomography of the Eye
NCT02614625
Optical Coherence Tomography Comparative Study
NCT00069199
Retinal Nerve Fiber Layer Thickness Analysis With Cirrus HD OCT Versus Stratus Optical Coherence Tomography (OCT)
NCT00766389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
spectral domain-OCT
Spectral domain-OCT scanning performed.
Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)
macular cube scanning
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)
macular cube scanning
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* myopic eyes
* hypermetropic eyes
Exclusion Criteria
* cataract
* previous ocular trauma or surgery(other than cataract surgery or refractive surgeries)
16 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Ophthalmology, Gangnam Severance Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sung Soo Kim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Ophthalmology, Yonsei University College of Medicine, Gangnam Severance Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yonsei University College of Medicine, Gangnam Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3-2008-0048
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.